These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 9639509)
1. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Zhong D; Saenko EL; Shima M; Felch M; Scandella D Blood; 1998 Jul; 92(1):136-42. PubMed ID: 9639509 [TBL] [Abstract][Full Text] [Related]
2. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa. Wakabayashi H; Fay PJ J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831 [TBL] [Abstract][Full Text] [Related]
3. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Scandella D Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680 [TBL] [Abstract][Full Text] [Related]
4. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Scandella D; Gilbert GE; Shima M; Nakai H; Eagleson C; Felch M; Prescott R; Rajalakshmi KJ; Hoyer LW; Saenko E Blood; 1995 Sep; 86(5):1811-9. PubMed ID: 7544643 [TBL] [Abstract][Full Text] [Related]
5. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754 [TBL] [Abstract][Full Text] [Related]
6. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Scandella D Vox Sang; 1996; 70 Suppl 1():9-14. PubMed ID: 8869462 [TBL] [Abstract][Full Text] [Related]
7. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Scandella D; Mattingly M; Prescott R Blood; 1993 Sep; 82(6):1767-75. PubMed ID: 7691236 [TBL] [Abstract][Full Text] [Related]
8. Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII. Yada K; Nogami K; Ogiwara K; Shibata M; Shima M Thromb Haemost; 2011 Jun; 105(6):989-98. PubMed ID: 21437361 [TBL] [Abstract][Full Text] [Related]
9. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Barrow RT; Healey JF; Gailani D; Scandella D; Lollar P Blood; 2000 Jan; 95(2):564-8. PubMed ID: 10627463 [TBL] [Abstract][Full Text] [Related]
10. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII. Scandella D Semin Thromb Hemost; 2002 Jun; 28(3):291-6. PubMed ID: 12098091 [TBL] [Abstract][Full Text] [Related]
11. A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX. Bloem E; Meems H; van den Biggelaar M; Mertens K; Meijer AB J Biol Chem; 2013 Sep; 288(36):26105-26111. PubMed ID: 23884417 [TBL] [Abstract][Full Text] [Related]
12. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905 [TBL] [Abstract][Full Text] [Related]
13. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Scandella D; Mattingly M; de Graaf S; Fulcher CA Blood; 1989 Oct; 74(5):1618-26. PubMed ID: 2477082 [TBL] [Abstract][Full Text] [Related]
14. Structural basis for inhibition of coagulation factor VIII reveals a shared antigenic hotspot on the C1 domain. Childers KC; Cowper B; Vaughan JD; McGill JR; Davulcu O; Lollar P; Doering CB; Coxon CH; Spiegel PC J Thromb Haemost; 2024 Sep; 22(9):2449-2459. PubMed ID: 38849084 [TBL] [Abstract][Full Text] [Related]
15. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets. Saenko EL; Scandella D; Yakhyaev AV; Greco NJ J Biol Chem; 1998 Oct; 273(43):27918-26. PubMed ID: 9774404 [TBL] [Abstract][Full Text] [Related]
16. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785 [TBL] [Abstract][Full Text] [Related]
17. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Fijnvandraat K; Celie PH; Turenhout EA; ten Cate JW; van Mourik JA; Mertens K; Peters M; Voorberg J Blood; 1998 Apr; 91(7):2347-52. PubMed ID: 9516133 [TBL] [Abstract][Full Text] [Related]
18. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Prescott R; Nakai H; Saenko EL; Scharrer I; Nilsson IM; Humphries JE; Hurst D; Bray G; Scandella D Blood; 1997 May; 89(10):3663-71. PubMed ID: 9160671 [TBL] [Abstract][Full Text] [Related]
19. Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study. Venkateswarlu D BMC Struct Biol; 2010 Feb; 10():7. PubMed ID: 20184747 [TBL] [Abstract][Full Text] [Related]
20. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Scandella DH Semin Thromb Hemost; 2000; 26(2):137-42. PubMed ID: 10919405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]